ThermoCool SmartTouch force-sensing catheter
Biosense Webster, a subsidiary of Johnson & Johnson (JNJ), announced the launch of its ThermoCool SmartTouch catheter in August 2016. The device is used for the treatment of patients with catheter ablation. Its porous tip design and contact force technology with 3-D (three-dimensional) mapping and navigation facilities enhance procedure efficiency.
OneTouch Via insulin patch
Johnson & Johnson acquired Calibra Medical in July 2012, which helped JNJ expand its diabetes business. Calibra’s wearable insulin delivery patch provided an innovative product for Johnson & Johnson, which could prove to be a successful alternative to insulin injections.
The mealtime insulin delivery device was approved by the FDA (U.S. Food and Drug Administration) in 2012. It’s slated for launch four years later due to the company’s streamlining and automation processes for the patch production.
Johnson & Johnson plans to launch the device in select markets in the United States by the end of 2016. The device can be worn for three days, and the dosage is controlled by a button.
Automated insulin delivery system
Another long-awaited diabetes care product is Johnson & Johnson’s automated insulin delivery system. It’s manufactured in partnership with DexCom (DXCM). A trial set is expected to start by the end of 2016. The US launch is slated for before November 2017.
The product’s integrated algorithm makes smart predictions and adjustments of insulin dosage, enabling automatic control of insulin delivery. Medtronic’s (MDT) MiniMed 670G, slated for launch by April 2017, is one of the competing products.
Another company that provides diabetes care devices in the United States is Abbott Laboratories (ABT).
Investors can gain exposure to JNJ’s growth by investing in the iShares S&P 500 Growth ETF (IVW), which holds approximately 1.8% of its total holdings in JNJ.
Variable Angle Locking Hand System
In July 2016, the Depuy Synthes trauma unit launched its hand locking system for the treatment of fractures and deformities. The technology allows the adjustment of the insertion angles for screws according to the fracture and anatomy of the patient. The device is expected to reduce soft-tissue irritation risk.
Next, let’s look at Johnson & Johnson’s recent strategic partnerships and collaborations.